CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils
Pei Wang,Ming-Hao Xu,Wen-Xin Xu,Zi-Ying Dong,Ying-Hao Shen,Wen-Zheng Qin
DOI: https://doi.org/10.2147/jhc.s450468
2024-05-08
Journal of Hepatocellular Carcinoma
Abstract:Pei Wang, 1, 2, &ast Ming-Hao Xu, 3, &ast Wen-Xin Xu, 3, &ast Zi-Ying Dong, 4 Ying-Hao Shen, 3 Wen-Zheng Qin 1 1 Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 2 Department of Digestive Medicine, Wuwei People's Hospital, Wuwei City, Gansu Province, 733000, People's Republic of China; 3 Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; 4 Department of CT/MRI Center, Wuwei People's Hospital, Wuwei City, Gansu Province, 733000, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wen-Zheng Qin, Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China, Tel/Fax +86-21-64041990, Email Ying-Hao Shen, Department of Liver Surgery and Transplantation, Liver Cancer Institute and Zhongshan Hospital, Fudan University, No. 180, Fenglin Road, Shanghai, 200032, People's Republic of China, Tel/Fax +86-21-64041990, Email Background: Anti-programmed death-1 (PD1) antibodies have changed the treatment landscape for hepatocellular carcinoma (HCC) and exhibit promising treatment efficacy. However, the majority of HCCs still do not respond to anti-PD-1 therapy. Methods: We analyzed the expression of CXCL9 in blood samples from patients who received anti-PD-1 therapy and evaluated its correlation with clinicopathological characteristics and treatment outcomes. Based on the results of Cox regression analysis, a nomogram was established for predicting HCC response to anti-PD-1 therapy. qRT‒PCR and multiple immunofluorescence assays were utilized to analyze the proportions of N1-type neutrophils in vitro and in tumor samples, respectively. Results: The nomogram showed good predictive efficacy in the training and validation cohorts and may be useful for guiding clinical treatment of HCC patients. We also found that HCC cell-derived CXCL9 promoted N1 polarization of neutrophils in vitro and that AMG487, a specific CXCR3 inhibitor, significantly blocked this process. Moreover, multiple immunofluorescence (mIF) showed that patients with higher serum CXCL9 levels had greater infiltration of the N1 phenotype of tumor-associated neutrophils (TANs). Conclusion: Our study highlights the critical role of CXCL9 as an effective biomarker of immunotherapy efficacy and in promoting the polarization of N1-type neutrophils; thus, targeting the CXCL9-CXCR3 axis could represent a novel pharmaceutical strategy to enhance immunotherapy for HCC. Keywords: CXCL9, anti-PD-1 antibody, N1 polarization of neutrophils, nomogram Hepatocellular carcinoma (HCC) is the most common type of liver cancer and is often diagnosed at advanced stages when surgical resection is contraindicated. 1 Therefore, systemic treatment is the main treatment option for patients with advanced HCC. Standard first-line treatment options for HCC typically include sorafenib, lenvatinib, and other kinds of immunotherapy. In addition, combination treatment regimens have shown promising results. Atezolizumab in combination with bevacizumab is now recommended based on the IMbrave150 Phase III trial results. 2,3 Other combinations, such as targeted therapy combined with immunotherapy or immunotherapy combined with antiangiogenic drugs, are being rigorously evaluated for their efficacy and adverse effects in large clinical trials. 4 In theory, due to the different mechanisms of action of two drugs in a combination therapy, synergistic effects can be exerted to maximize the antitumor benefits. Moreover, toxicity is not additive. 5 In addition, with the advancements in systematic treatment, neoadjuvant therapy and adjuvant therapy for HCC have also received increasing amounts of attention. 6 The postoperative adjuvant atezolizumab combined with bevacizumab has also been proven to prolong the progression-free survival of HCC patients. 7 The PD-1/PD-L1 pathway represents a key immune checkpoint that tumors utilize to evade immune surveillance. Thus, blockade of the PD-1/PD-L1 pathway has revolutionized cancer immunotherapy, leading to significant improvements in patient outcomes across multiple tumor types, including HCC. 8 PD-1 inhibitors, such as nivolumab 9 and pembrolizumab, 10 have shown promising activity in the treatment of HCC. These agents restore the function of T cells, unleashing the immune system on tumors and leading to durable tumor res -Abstract Truncated-
oncology